Fourth-line therapy with amrubicin (40 mg/m2) rapidly resulted in consolidation and wall thickening in the right lower lobe (Figure 3(b)), with almost normal infection-related marker values: WBC count of 12.2 × 109/L and CRP level of 1.68 mg/L. This evidence concerns the gene CRP and infection.